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Peroxiredoxin 5 is the last discovered mammalian member of an ubiquitous family of peroxidases widely 
distributed among prokaryotes and eukaryotes. Mammalian peroxiredoxin 5 has been recently classified as an 
atypical 2-Cys peroxiredoxin due to the presence of a conserved peroxidatic N-terminal cysteine (Cys47) and an 
unconserved resolving C-terminal cysteine residue (Cys151) forming an intramolecular disulfide intermediate in 
the oxidized enzyme. We have recently reported the crystal structure of human peroxiredoxin 5 in its reduced 
form. Here, a new crystal form of human peroxiredoxin 5 is described at 2.0 Ǻ resolution. The asymmetric unit 
contains three polypeptide chains. Surprisingly, beside two reduced chains, the third one is oxidized although the 
enzyme was crystallized under initial reducing conditions in the presence of 1 mM 1,4-dithio-DL-threitol. The 
oxidized polypeptide chain forms an homo-dimer with a symmetry-related one through intermolecular disulfide 
bonds between Cys47 and Cys151. The formation of these disulfide bonds is accompanied by the partial 
unwinding of the N-terminal parts of the α2 helix, which, in the reduced form, contains the peroxidatic Cys47 
and the α6 helix, which is sequentially close to the resolving residue Cys151. In each monomer of the oxidized 
chain, the C-terminal part including the α6 helix is completely reorganized and is isolated from the rest of the 
protein on an extended arm. In the oxidized dimer, the arm belonging to the first monomer now appears at the 
surface of the second subunit and vice versa. 
Keywords: antioxidant enzyme; peroxiredoxin; thioredoxin fold; thioredoxin peroxidase; crystal structure 
Abbreviations used: PRDX, human peroxiredoxin; Prdx, mouse and rat peroxiredoxin; 1hd2, RCSB Protein 
Data Bank code of the tetragonal form of human PRDX5; ROS, reactive oxygen species; RNS, reactive nitrogen 
species; MALDI, matrix-assisted laser desorption/ ionization. 
 
INTRODUCTION 
Peroxiredoxins (PRDXs) constitute a family of ubiquitous peroxidases found in all biological kingdoms.
1-5
 
PRDXs reduce hydrogen peroxide, alkyl hydroperoxides and peroxynitrite by the use of reducing equivalents 
derived from thiol-containing donor molecules such as thioredoxin, glutathione, tryparedoxin, alkyl 
hydroperoxide reductase flavoprotein oxidoreductase component (AhpF) and cyclophilin A.
6-10
 
Six PRDX isoforms have been identified and characterized in mammals.
5
 Mammalian PRDXs appear to act as 
regulators of hydrogen peroxide-mediated signal transduction.
4,11
 However, the specific subcellular localization 
of certain PRDXs in organelles that are sources of reactive oxygen species (ROS) or reactive nitrogen species 
(RNS), their abundance in many different cell types exposed to high levels of ROS and RNS, and findings that 
specific inhibition of individual PRDXs renders cells more sensitive to H2O2 toxicity, lipid peroxidation and 
apoptosis, argue that PRDXs are also important protective antioxidant enzymes in mammals.
12-14
 Moreover, 
recent reports on Prdx1, Prdx2 and Prdx6 inactivations by homologous recombination in mice revealed that 
these members of mammalian PRDXs are indeed essential enzymes involved, in vivo, in the protection of 
mammalian cells against deleterious oxidations caused by ROS.
15-17
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Figure 1. (a) Topological diagram showing the arrangement of the secondary structural elements in PRDX5. The helices 
are represented as cylinders and the β strands as arrows. The beginning and the end of the secondary structural elements are 
labeled. The green hatching is only present in the reduced chains (A and B) and the green dashes represent the α6 helix in 
the oxidized chain C. The three helices and the four β-strands belonging to the thioredoxin fold are colored green and red, 
respectively while the remaining elements are colored yellow, (b) Alignment of the Cα atoms of the three independent 
polypeptide chains with those of lhd2. The graph shows the distance of each Cα atom from the corresponding C atom in lhd2. 
Chain A is black, chain B is red and chain C is green. 
 
All PRDXs exhibit a conserved peroxidatic cysteine residue in their N-terminal region that attacks the peroxide 
and is consequently oxidized to cysteine sulfenic acid (Cys-SOH).
12
 Originally, PRDXs were divided into two 
subgroups, the 1-Cys and the 2-Cys PRDXs, depending on the number of cysteine residues directly involved in 
catalysis. Mammalian PRDXs are now divided into three subgroups referred to as typical 2-Cys (PRDX1-4), 
atypical 2-Cys (PRDX5) and 1-Cys (PRDX6) PRDXs.
5
 In the typical 2-Cys subgroup, the second redox-active 
cysteine, the resolving cysteine, is localized to the C-terminal region of the enzyme in a conserved domain. 
During peroxidase reaction, the cysteine sulfenic acid from one subunit is attacked by the resolving cysteine of 
another subunit resulting in the formation of a stable intersubunit disulfide bond which can then be reduced by 
thioredoxin or cyclophilin to regenerate the enzyme.
12,10
 In atypical 2-Cys PRDXs, the C-terminal resolving 
cysteine is contained within the same polypeptide chain and the reaction with the peroxidatic cysteine results in 
the formation of an intramolecular disulfide bond. PRDX5, the only mammalian atypical 2-Cys PRDX identified 
so far, uses thioredoxin to reduce the disulfide.
12
 Finally, in 1-Cys PRDXs only the N-terminal peroxidatic 
cysteine is conserved and the resolving cysteine residue is missing. The peroxidatic cysteine sulfenic acid formed 
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PRDX5, previously named PrxV, AOEB166, PMP20 or ACR1, is the last member of mammalian PRDXs that 
has been cloned and characterized.
12,18-22 
Human PRDX5 can be addressed to several subcellular compartments 
such as mitochondria, peroxisomes, the nucleus and the cytosol.
12,18-21
 In a previous report, we presented a 
crystal structure of human PRDX5 in its reduced form.
22
 The structure revealed that peroxidatic Cys47 and 
resolving Cysl51 were too distant to form an intramolecular disulfide bond upon oxidation without important 
conformational changes. Also, the enzyme did not form a dimer like other PRDXs (typical 2-Cys and 1-Cys 
PRDXs) for which dimers are observed in solution and in the crystal, formed by antiparallel association of two 
β-strands independent of oxidizing or reducing conditions.5,22 
Here, we report the crystal structure of a covalent dimeric form of oxidized human PRDX5 at 2.0 Ǻ. 
Intermolecular disulfide bonds are formed between peroxidatic Cys47 and resolving Cys151 of two different 
polypeptide chains. However, SDS-PAGE and mass spectrometry analyses show that, upon oxidation, the major 
form is still the PRDX5 with intramolecular disulfide bond between Cys47 and Cys151. Moreover, we report 
here that reduced as well as oxidized PRDX5 form contacts which are different from antiparallel association of 
β-strands observed in typical 2-Cys and 1-Cys PRDXs. PRDX5 contacts are compatible with the formation of 
non-covalent dimers in solution. 
RESULTS 
Quality of the structure and overall description 
The structure refined at 2.0 Ǻ resolution contains three polypeptide chains labeled A-C in the asymmetric unit. 
Chains A and B are in the reduced form while chain C is oxidized and forms a dimer by means of disulfide 
bonds with a symmetry-related chain C. In the three polypeptides, the electron density is well defined along the 
main chains and for most of the side-chains. It is somewhat more ambiguous at the level of the side-chains of 
some residues surrounding the disulfide bond in chain C. These regions are also characterized by large thermal 
motions. The analysis of the Ramachandran plot (not shown) computed with the program PROCHECK
23
 shows 
that 87.8% of the non-glycine residues are in the most favored region and there are no residues in disallowed 
regions. A topological diagram comparing the secondary structures of the three chains is presented in Figure 
1(a). In each of them, the overall structure is characterized by the presence of a thioredoxin fold consisting of a 
four-stranded β-sheet and three α-helices24 although in the third chain (C), the last helix (α6) is no longer 
flanking the β-sheet, since it is completely displaced from its usual position in a thioredoxin fold. Each 
polypeptide chain comprises three additional α-helices and three β-strands, one of which is associated with the 
thioredoxin β-sheet to form a fifth strand, while the two remaining ones form an additional two-stranded β-sheet 
in the N-terminal part of the chain. 
SDS-PAGE analysis 
SDS-PAGE   analysis   of   recombinant   PRDX5 
oxidized with increasing concentration of H2O2 (Figure 2(a)) or reduced by increasing concentration of DTT 
(Figure 2(b)) showed that the denatured recombinant protein may exist as monomeric (Mox) and dimeric (Dox) 
oxidized forms as well as monomeric reduced form (Mred). However, the dimeric oxidized form appears always 
as a minor band compared to monomeric oxidized PRDX5 even after exposure to a high concentration of H2O2 
(500 µM). SDS-PAGE analysis established that recombinant PRDX5 is isolated in the oxidized form, since the 
protein migrates as a minor oxidized dimeric form and a major monomeric oxidized form without prior oxidation 
by H2O2 (Figure 2(a) and (b)). As the DTT concentration was increased, the minor dimeric oxidized form 
decreased from 1 mM DTT to disappear completely at 10 mM and 100 mM DTT. However, as H2O2 used to 
oxidize PRDX5 was not removed prior to adding the reductant, part of the DTT is likely oxidized by the excess 
of H2O2. Concomitantly, a small upward shift in the migration of the monomeric form is observed upon 
reduction (Figure 2(b)), consistent with intramolecular disulfide bond reduction as confirmed by mass 
spectrometry analysis (see below and Figure 2(c)). Also, the use of N-ethylmaleimide (10 mM) to block free 
thiol groups in oxidized PRDX5 indicated that no detectable thiol-disulfide interchange occured during protein 
denaturation for SDS-PAGE analysis (data not shown). 
Gel filtration analysis 
Analysis of recombinant PRDX5 on a gel filtration column with or without 10 mM DTT yielded a major peak 
with maxima at identical retention times and consistent with a dimeric 38 kDa protein (Figure 2(d)). However, 
for the oxidized form, an asymmetrical peak with an extended tail on the low molecular mass side is observed. 
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This suggests that, under native conditions, the oxidized protein is mainly a dimer but in rapid equilibrium with a 
minor monomeric form. Gel filtration analyses carried out under reducing or non-reducing conditions using 
PRDX5 for which free thiol groups were blocked by N-ethylmaleimide (10 mM), showed a major peak 
consistent with a dimeric 38 kDa protein (data not shown). 
Mass spectrometry analysis 
Mass spectrometry analysis of the tryptic fragments of monomeric (Mox) and dimeric (Dox) oxidized forms as 
well as monomeric reduced form (Mred) of recombinant PRDX5, confirmed the existence of a disulfide bond 
between Cys47 and Cysl51 in Mox and Dox forms. Indeed, the matrix-assisted laser desorption/ionization 
(MALDI)-time-of-flight analysis of the tryptic fragments of Mox and Dox forms showed the presence  of  two  
ions   [M + H+]   3860•0134  and 3988•1089 corresponding, respectively, to the following peptides linked by a 
disulfide bridge (Cys47-Cys151): GVLFGVPGAFTPGCys
47





SK and ALN VEPDGTGLTTCys
151
SLAPNIISQL (Figure 
2(c)). Moreover, these ions were not present after reduction and carboxymethylation of the tryptic peptides of the 
Mox and Dox forms of PRDX5 (data not shown). A minor ion ([M + H
+
] 4530•2871) corresponding to the 
peptides linked by the disulfide bridge (Cys72-Cys151) was also observed. In contrast, the MALDI-time-of-
flight analysis of the Mred form showed the presence of ions corresponding to reduced peptides ([M + H
+
] 
1664•8828, 2207•0913 and 2326•1958). 
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Figure 2. SDS-PAGE analysis of PRDX5 under (a) oxidizing or (b) reducing conditions, (c) Analysis by mass spectrometry 
of tryptic peptides of reduced and oxidized PRDX5 forms examined in (a) and (b). (a) PRDX5 was incubated with various 
concentrations of H2O2 and subjected to non-reducing SDS-PAGE. Major monomeric (Mox) and minor dimeric (Dox) 
oxidized forms of PRDX5 are indicated by arrows. In (b), PRDX5 was first incubated with 500 µM H2O2 and then subjected 
to increasing concentrations of DTT. Monomeric (Mox) and dimeric (Dox) oxidized forms as well as monomeric reduced 
form (Mred) are indicated by arrows. In (c) mass spectrometric analysis of the tryptic fragments of Mox, Dox and Mred 
confirmed the existence of a disulfide bond between Cys47 and Cys151 in Mox and Dox. (d) Gel filtration analysis of 
recombinant PRDX5 under non-reducing and reducing conditions with 10 mM DTT. For both conditions, the protein 
retention times correspond to a molecular mass of 36 kDa. Under non-reducing conditions, an asymmetrical peak is 
observed, suggesting a rapid equilibrium between a dimeric and a monomeric form. 
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Figure 3. (a) and (b) Ribbon diagrams showing the overall organization of the new structure of PRDX5, colored 
as for Figure 1(a). The reduced chain A is in (a) and the oxidized chain C in (b); they are presented in the same 
orientation. The side-chains of the two Cys residues involved in the catalytic mechanism are represented as balls 







Comparison of reduced and oxidized forms of PRDX5 monomers 
The 161 C
α
 atoms of the three polypeptide chains A, B and C were aligned with those of the previously 
determined structure 1hd2.
22
 The results are presented in Figure 1(b). The RMS deviation for chains A and B is 
very small, 0.406 A and 0.444 Ǻ, respectively, while it is as large as 8.565 Ǻ for chain C. For this chain, the 
largest differences occur in the regions containing the Cys residues (47 and 151) involved in the formation of 
inter-molecular disulfide bridges. An alignment of chain C without residues 47-50 and 146-161 reduces the RMS 
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deviation to 0.391 Ǻ. Figure 3(a) shows ribbon diagrams comparing chains A and C in the same orientation. 
Since it appears that the overall folding of the reduced chains A and B is extremely similar to the one described 
for the tetragonal (pdb:1hd2) crystal form of PRDX5,
22
 it will not be discussed further but will be used for a 
detailed comparison with chain C. 
The first important reorganization observed in the oxidized chain C concerns the region involving the peroxidatic 
residue Cys47. In the reduced structure, this residue is part of the kinked α2 helix and it is located in a positively 
charged pocket exposed to the solvent. Moreover, the sulfur atom of Cys47 is in close interaction with the N
ηl 
atom of Arg127, which is responsible for the positive charge. It is also in contact with the O
γ1
 atom of Thr44 
located at the N-terminal part of the α2 helix and with an oxygen atom of a benzoate ion which restricts the 
access to the cavity containing Cys47.
22
 In the oxidized chain C, a large fragment of the N-terminal part of the 
α2 helix (residues 44-50) is completely unwound. Even if the residues 44-46 still show some helical appearance 
superimposable on the same residues of the reduced form, this short fragment does no longer belong to the α2 
helix in the oxidized chain C. It is worth noting that the kinked part of this helix is located at the C-terminal end 
and is not concerned with the unwinding observed in the oxidized chain. The peroxidatic residue Cys47 now 
appears in a large loop (residues 39-50) and is completely exposed if one considers only one monomer. Also, 
Cys47 has lost the contacts with N
η1
 of Argl27 (>6Ǻ) and Oγ1 of Thr44 (>10Ǻ). Furthermore, the benzoate ion 
has completely disappeared. The unwinding of the active-site helix has been described
25-27
 in typical 2-Cys 
PRDX structures, and is thought to play an important role in the disulfide bond formation between the 
peroxidatic and resolving cysteine residues. In hORF6
28
 (human PRDX6, member of the 1-Cys PRDX 
subgroup), the peroxidatic oxidized cysteine Cys47 exists as a reactive cysteine sulfenic acid. It is located at the 
N-terminal part of the α2 helix and is not involved in a disulfide bond. On the other hand, in HBP2325 (rat Prdx1, 
member of the typical 2-Cys PRDX subgroup) the α2 helix is unwound at its N-terminal end, which contains the 
corresponding peroxidatic residue Cys52. The latter forms a disulfide bond with the resolving cysteine, Cys173, 
of another polypeptide chain resulting in the formation of a dimer between these two chains. In the case of TPx-
B
26
 (human PRDX2, member of the typical 2-Cys subgroup), the peroxidatic residue is oxidized to sulfinic acid 
(Cys-SO2H), an inactive form impeding the formation of a disulfide bond and remains in the wound α helix. The 
recently solved crystal structure of the Haemophilus influenza hybrid-Prx5
27
 (hyPrx5) also supports the idea that 
the unwound structure would be important in disulfide bond formation. Indeed, two independent polypeptide 
chains are present in the asymmetric unit of hyPrx5. In one of these independent chains, the wound conformation 
of the active-site helix is conserved whilst in the other this helix is unwound at its N-terminal part. This 
conformational change shortens the distance between the peroxidatic cysteine, Cys49, which becomes a part of a 
loop, and the resolving cysteine, Cys180, of another sub-unit, bringing the two cysteine residues into the distance 
needed for disulfide bond formation. 
The second region undergoing important rearrangements in the oxidized form of human PRDX5 is in the 
surroundings of resolving Cys151. In the reduced form, this residue is located in the loop between the β7 strand 
and the α6 helix and it is well exposed to the exterior. The α6 helix, which immediately follows is folded at the 
surface of the protein and covers the β6 and β7 strands in a direction more or less perpendicular to the strands, 
giving rise to a salt-bridge between Gln160 (α6) and Asn141 (β7), as well as many hydrophobic contacts with 
the α2 helix and the β6 strand. These contacts involve on one side Ilel57, Ile158 and Leu161 in the α6 helix, and 
on the other side Leu62, Val67 and Val131. In the oxidized form, the situation is completely different and large 
modifications begin at residue 145 in the loop following the C-terminal end of the β7 strand. As shown in Figure 
3(b), the loop between the β7 strand and the α6 helix is completely reversed and brings the remaining part of the 
protein chain towards the exterior. The N-terminal part of the α6 helix is also unwound for about four residues. 
This helix appears now at the end of an extended arm and is completely isolated from the rest of the protein. The 
intramolecular contacts described above for the reduced chain have disappeared and the hydrophobic residues 
involved in these contacts are exposed. Such a situation would be completely unrealistic if this part of the 
polypeptide was not incorporated in the formation of a dimer (see below). 
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Figure 4. (a) Ribbon diagram of the dimer composed of two oxidized chains C colored green and red. The Cys 
residues taking part in the two intermolecular disulfide bonds are shown. The C-terminal α6 helix of one subunit 
comes into close contact with the α2 helix and the β6 strand of the other subunit. (b) Molecular surface of the 
dimer colored according to the local electrostatic potential, ranging from blue (the most positive region) to red 
(the most negative) and presented in the same orientation as for (a). The positions of the Cys residues are 
indicated, (c) and (d) Speculation of the possible conformation of an oxidized monomer forming an 
intramolecular disulfide bond by refolding the extended arm shown in (a) over the same subunit in such a way 
that it takes exactly the place of the arm of the second subunit. Part (c) is oriented like part (a), and part (d) is 
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The dimeric oxidized form 
The presence of an oxidized form of PRDX5 was rather unexpected, since the crystallization was performed 
under reducing conditions in the presence of 1 mM 1,4-dithio-DL-threitol (DTT). Nevertheless, DTT is known 
to be rapidly oxidized in solution and the redox conditions are thus changing during the time for crystallization. 
It was proposed
12
 that, upon oxidation, PRDX5 would form intramolecular disulfide intermediates and is thus 
monomeric from this point of view. In spite of these biochemical data, the oxidized chain C forms a covalent 
dimer with a chain related by a 2-fold crystallographic axis. As shown in Figure 4(a), disulfide bonds are formed 
between Cys47 of one polypeptide chain and Cys151 of the symmetry related one, and vice versa. In this way, 
the α6 helix of one chain, at the end of its extended arm, comes in contact with the symmetry-related chain and 
regenerates in an intermolecular way exactly the same hydrophobic contacts with α2 and β6 which were 
observed in the reduced form in an intramolecular way. The hydrophobic residues are no longer exposed and 
even the Gln160-Asn141 salt-bridge reappears in the oxidized form. However, this salt-bridge is also 
intermolecular instead of intramolecular in the reduced chains. The two disulfide bonds of the dimer are very 
close to each other. They are located at the surface of a kind of widely opened cavity illustrated in Figure 4(b), 
which appears at the interface between the two monomers. 
The picture is becoming even more complicated as the gel filtration analysis indicates a probable rapid 
equilibrium between a monomeric and a dimeric form under native non-reducing conditions. Although, there is 
no clue to determine the covalent or non-covalent nature of this dimer, a simplistic one-state model of the 
oxidized enzyme could be misleading in the way for describing the catalytic mechanism of PRDX5. 
Proposed conformation of PRDX5 forming an intramolecular disulfide bond upon oxidation 
The comparison of the monomer shown in Figure 3(b) and the dimer shown in Figure 4(a) as well as SDS-PAGE 
and mass spectrometry analysis (Figure 2) suggest that the conformation of the oxidized monomeric form, that is 
based on biochemical data and expected in the catalytic mechanism,
12
 could be created by refolding the extended 
arm appearing in Figure 3(b) over the very same polypeptide chain in order to regenerate exactly the same 
contacts observed in the dimer (Figure 4(a)), including the Cys47-Cys151 disulfide bond, but in an 
intramolecular way. Compared to chain C, this reorganization would only involve two residues (146-147) and 
the results of these speculations are shown in Figure 4(c) and (d). In this simulation, the peroxidatic Cys47 
remains in the unwound part of the α2 helix and this unwinding appears thus to be essential in the disulfide bond 
formation with the resolving Cys151 either in an intramolecular way or in an intermolecular way. As shown in 
Figure 4(c) and (d), the intramolecular disulfide bond appearing in this simulation between Cys47 and Cys151 
would be accessible for reduction by thioredoxin according to the proposed mechanism.
12
 
The packing of the polypeptide chains in comparison with other PRDX structures 
Crystal structures are available for the typical 2-Cys PRDXs,
25,26,29,30
 for one atypical 2-Cys PRDX;
22,31
 for one 
hybrid PRDX5
27
 related to the previous category and for one 1-Cys PRDX.
28
 The typical 2-Cys PRDX and the 
1-Cys PRDX subgroups are characterized by the formation of a dimer, which is observed independently of the 
reduced or oxidized state of the protein. This dimer is formed by the antiparallel association of two β-strands (β7 
of each monomer) belonging to the thioredoxin fold, resulting in a ten-stranded (or more) β-sheet in the dimer. 
This kind of dimmer is not observed in the known structures of atypical 2-Cys PRDX (PRDX5) and the present 
study confirms the absence of such dimers in the reduced as well as in the oxidized forms of PRDX5. As shown 
in Figure 4(a), the dimerization of the oxidized PRDX5 chains by formation of two intermolecular disulfide 
bonds does not at all associate the β-sheets of the two monomers. Consequently, if the dimers observed in typical 
2-Cys PRDXs do not exist in atypical 2-Cys PRDXs, the decamer formed by association of five dimers
26,29,30
 in 
typical 2-Cys PRDXs and stabilized by the reduced form of the active-site disulfide
5
 is also non-existent. 
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In the crystal structure of hyPrx5,
27
 the existence of PRDX-PRDX dimers was discovered and the authors 
pointed out that the same contacts exist in the human PRDX5 structure, 1hd2.
22
 The contacts involve residues in 
the β3-α2 loop (residues 43-45), in the a3 helix (residues 79-81), in the β5-a4 loop (residues 100-101) and in the 
α5 helix (residues 117-120) which is characteristic of PRDX5, since it is not observed in other PRDXs 
structures. We also observe the same non-covalent dimerization in this new structure of PRDX5. The reduced 
chain A is in contact with a symmetry-related (2-fold axis) chain A (Figure 5(a)), while the reduced chain B is in 
contact with the oxidized chain C (Figure 5(b)). In each case, the salt-bridge Arg124-Asp77 described in 
hyPrx5
27
 is also present. The other contacts are mainly hydrophobic and it is worth noting that intermolecular 
Phe43-Phe43 contacts are present in the interaction between two reduced chains as well as between an oxidized 
chain and a reduced one, in spite of the localization of this residue in one of the region undergoing important 
reorganizations in the oxidized form. This non-covalent interaction may thus be present under oxidizing 
conditions and be responsible of the dimeric form observed by gel filtration (Figure 2(d)). Interestingly, the four 
contacts described above (the β3-α2 loop, the α3 helix, the β5-α4 loop, the α5 helix) exactly correspond to the 
four interfacial regions labelled I-IV in the formation of (α2)5 decamers in the subgroup of classical 2-Cys 
PRDX.
5,30
 Even the α5 helix, which is present only in PRDX5 (atypical 2-Cys PRDX), appears as a kind of 
inclusion in the region IV of typical 2-Cys PRDXs. It was noticed that the decamer formation was favored in the 
reduced state and that the oxidized decameric structure of AhpC
30
 corresponded to a metastable oligomerization 
intermediate whose presence could be due to the high protein concentration during crystallization. It is very 
possible that the same kind of metastable association appears when an oxidized chain of PRDX5 is involved in 
these non-covalent contacts and that the resulting instability could explain the probable rapid equilibrium 
between a monomeric and a dimeric form in native non-reducing conditions suggested by the gel filtration 
analysis. 
On the other hand, since the oxidized chain C is also linked to another symmetry-related chain C by    disulfide    
bonds,    tetramers    (Figure 5(b)) composed of chains B:C:C:B may appear and this oligomerization, which 
occurs only in presence of the covalent dimeric oxidized PRDX5, is thus redox-dependent. 
Table 1. Data collection and refinement statistics 
Wavelength (Ǻ) 0.8441 
Resolution range (Ǻ)  
   Overall (ov) 40.0-2.0 
   Highest shell (hs) 2.05-2.0 
Reflections  
   Total 164,737 
   Unique 38,821 
Completeness (%) (ov/hs) 96.9/95.2 
Rmerge 0.047 
Number of non-hydrogen atoms used in refinement  
   Protein atoms 3576 
   Heterogen atoms 18 
   Solvent atoms 62 
R-factor (ov/hs) 0.221/0.286 
Rfree (ov/hs) 0.259/0.355 
RMS deviation from ideality  
   Bonds (Ǻ) 0.021 
   Angles (deg.) 1.9 
Estimated overall coordinate error (Ǻ)  
   Based on Rfree 0.168 
   Based on maximum likelihood 0.175 
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Figure 5. (a) Ribbon diagram of the non-covalent dimer between the reduced chain A and a symmetry related 
chain A. The projection is along the crystallographic 2-fold axis relating the two chains. The models are 
progressively colored from blue (N terminus) to red (C terminus). The regions involved in the contacts are 
labeled, (b) Ribbon diagram colored as in (a) of the tetramer formed by the association of chains B(reduced): 
C(oxidized):C(oxidized):B(reduced). The B:C and C:B contacts are non-covalent and similar to those observed 
between the two reduced chains A; the C:C contacts involve two intermolecular disulfide bonds. The side-chains 
of the peroxidatic and resolving Cys residues are shown. The projection is along the crystallographic 2-fold axis 
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 MATERIALS AND METHODS 
Crystallization 
The expression and purification of recombinant human PRDX5 have been described.
18,22
 The crystals of the 
His6-tagged molecule were grown under reducing conditions by hanging-drop, vapor-diffusion at 291 K with the 
well solution consisting of 20% (w/v) polyethylene glycol (PEG) 3350 as precipitant, 0.1 M sodium citrate 
buffer (pH 5.3), 1 mM 1,4-dithio-DL-threitol (DTT) as reductant and 0.02% (w/v) sodium azide. The hanging-
drop was formed by mixing 2 µl of the protein solution (10 mg ml
-1
) with 2 µl of the well solution. Crystals with 
typical dimensions of 0.15 mm appeared after about five days and deteriorated a few days later. It was suggested 
that this degradation could be the result of the oxidation of the protein molecule after the growth of the crystal. 
This oxidation could result in some conformational changes incompatible with the crystal packing. 
Data collection, structure determination and refinement 
Before data collection, the crystals were cryo-soaked in a solution identical with the mother liquor but containing 
15% (v/v) glycerol and flash-cooled at 100 K. The data were collected on beam-line BW7B at EMBL c/o Desy 
(Hamburg, Germany) using an MAR345 imaging-plate detector. A resolution of 2.0 Å was achieved using a 
wavelength of 0.8441 Ǻ. The crystals are orthorhombic, space group C2221, with a = 79.20 Ǻ, b = 102.05 Ǻ, c 
= 145.06 Ǻ. The volume of the unit-cell suggests the presence of three polypeptide chains in the asymmetric unit 
(VM
32
 = 2.89 Ǻ3/Da). All the measurements were indexed and integrated using the programme DENZO33 and 
merged with the programme SCALEPACK.
33
 Statistics of data collection and processing are given in Table 1. 
The presence of non-crystallographic symmetry (NCS) was investigated using the programme MOLREP
34
 of the 
CCP4 suite
35
, applied to data comprised between 7.0 Ǻ and 4.0 Ǻ. This resulted in the clear indication of an NCS 
2-fold axis corresponding to the polar coordinates (θ = 90°, φ = 38.5°, χ = 180°) and thus located in the (a,b) 
plane. Furthermore, a Patterson function computed at a resolution of 3.5 Ǻ did not indicate the presence of a pure 
translation between NCS related chains. These results suggest the presence of only two polypeptide chains in the 
asymmetric unit, but this situation would correspond to a more unlikely value of VM = 4.34 Ǻ
3
/Da. The 
resolution of the crystal structure was attempted by the molecular replacement method using the programme 
AMoRe
36
 applied to data between 20.0 Ǻ and 3.5 Ǻ and the structure 1hd2 as a model. Looking for two 
independent polypeptide chains, two different solutions with similar figures of merit were found. One of the two 
chains present in the two solutions was the same while the remaining one was different. An examination of the 
packing with the programme O
37
 showed that, in both cases, large cavities were present in which the remaining 
chain could fit perfectly, indicating the presence of three polypeptide chains in the asymmetric unit, which will 
be labelled A, B and C. An analysis of the relationship between the three chains shows that the pairs A-B and A-
C are both related by the non-crystallographic 2-fold axis at (θ = 90°, φ = 38.5°, χ = 180°). The chains B and C 
are thus more or less parallel with each other but with a slight inclination preventing the apparition of a pure 
translation peak in the Patterson function. 
The structure was refined using the programme REFMAC5
38
 of the CCP4 suite.
35
 A rigid body refinement 
applied to data between 20 Ǻ and 2.75 Ǻ provided an R-value of 33.2%. At this stage, a visual examination with 
the programme O
37
 revealed that chains A and B were very similar to the model of the reduced form (lhd2) used 
for the molecular replacement and required only minor adjustments. On the other hand, in chain C it was 
necessary to retrace two fragments corresponding to residues 46-52 and 144-161. These two fragments contain 
the two cysteine residues (Cys47 and Cysl51) supposed to form an intramolecular disulfide bond in the oxidized 
form. A disulfide bond is indeed observed but it is intermolecular between two symmetry-related polypeptide 
chains C. The details are described in Discussion. The N-terminal His6 tag and the linker connecting the His6 tag 
to the protein were not observed except for one residue (SerO) in chain A. As it was also the case in the previous 
reduced crystal forms of PRDX5,
22,31
 a benzoate ion is observed close to the cleft containing the active-site 
Cys47 in the two reduced chains (A and B) but is not present in the oxidized chain C. A total of 62 ordered 
solvent molecules was incorporated by the programme ARP/wARP
39
 During the final steps, the hydrogen atoms 
were incorporated in riding positions and the mean-square displacements of rigid bodies were refined, each 
polypeptide chain being defined as a different TLS group. The final R value is 0.221 (Rfree = 0.259) for all 
available data to a resolution of 2.0 Ǻ. The final statistics of the refinement are given in Table 1. 
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SDS-PAGE analysis 
Electrophoresis of recombinant PRDX5 protein was carried out in SDS-12% (w/v) polyacrylamide gels.
40 
PRDX5 (10 µg) was incubated either with increasing concentrations of H2O2 for one hour at 37 °C or with 
increasing concentrations of DTT for five minutes at room temperature followed by five minutes at 95 °C. 
Several samples were also incubated with N-ethylmaleimide (10 mM) for 30 minutes at 37 °C to block free thiol 
groups in oxidized PRDX5 before SDS-PAGE analysis. Proteins were then subjected to non-reducing SDS-
PAGE and stained with Coomasie brilliant blue G-250. 
Gel filtration analysis 
Recombinant PRDX5 in 20 mM Tris-HCl buffer (pH 7.5) containing 150 mM NaCl and with 10 mM DTT 
(reducing conditions) or without DTT (non-reducing conditions) was applied onto an analytical Superdex 200 
column (HR 10/30; Amersham Pharmacia Biotech) using an Amersham Pharmacia AKTÄ Prime system. As 
previously indicated for SDS-PAGE analysis, samples were also treated with N-ethylmaleimide (10 mM) to 
block free thiol groups under non-reducing as well as reducing conditions. Analyses were performed at a flow 
rate of 0.4 ml/minute with monitoring by measurement at A280. 
Mass spectrometry analysis 
Proteins in the gel were excised using a 1 mm sample corer (Fine Science Tools Inc.). Excised gel pieces were 
placed in 1.5 ml polypropylene Eppendorf tubes and washed twice in 50 µl of 50 mM NH4HCO3. The gel pieces 
were destained and dehydrated with 50 µl of 50 mM NH4HCO3, 50% (v/v) CH3CN and then dried in a 
centrifugal evaporator. Enzymatic digestion was performed by the addition of 10 µl of trypsin (0.02 µg µl
_1
) 
(Promega Madison, WI, USA) in 25 mM NH4HCO3 to each gel piece, followed by overnight incubation at 37 
°C. For MALDI mass spectrometry, a 0.5 µl aliquot of the digestion supernatant was spotted onto a sample plate 
with 0.5 µl of matrix (5 mg ml
-1
 α-cyano-4-hydro-xycinnamic acid and 0.5 pmol µl-1 renin as internal standard in 
25% (v/v) ethanol, 25% (v/v) acetonitrile, 0.05% (v/v) trifluoroacetic acid) and allowed to air dry. MALDI mass 
spectrometry was performed using a Micromass Maldi™ spectrometer (Manchester, UK) equipped with a 337 
nm nitrogen laser. The instrument was operated in the positive reflectron mode at 20 kV accelerating voltage 
with time lag focusing. Spectra were internally calibrated using the renin peptide. An initial mass tolerance of 50 
ppm was used in all searches. 
Protein Data Bank accession numbers 
Final coordinates and structure factors have been deposited with the RCSB Protein Data Bank under accession 
numbers loc3 and rloc3sf, respectively. 
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